5-Methoxy-2-{[3-(trifluoromethyl)benzene-1-sulfonyl]amino}benzoic acid | 474448-66-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-Methoxy-2-{[3-(trifluoromethyl)benzene-1-sulfonyl]amino}benzoic acid
• 英文别名: 5-methoxy-2-[[3-(trifluoromethyl)phenyl]sulfonylamino]benzoic acid
• CAS: 474448-66-3
• 化学式: C₁₅H₁₂F₃NO₅S
• 分子量: 375.3
• InChiKey: XQMQEUIJEMPORB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• Sulfone-containing prodrugs
  申请人：Fulp Bradley Alan

  公开号：US20050267032A1

  公开（公告）日：2005-12-01

  Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfone-containing prodrugs, and compositions and methods utilizing sulfone-containing prodrugs that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.

  提供了一种在治疗疾病中通过调节电压依赖性钾通道中钾离子通量而有用的化合物、组合物和方法。更具体地，该发明提供了含砜的前药，以及利用含砜的前药的组合物和方法，通过阻断与所示疾病的发病或复发有关的钾通道，在治疗疾病中有用。该发明的化合物、组合物和方法可用于治疗的示例疾病包括镰状细胞病和青光眼。
• ANTHRANILAMIDES AND METHODS OF THEIR USE
  申请人：Brendel Joachim

  公开号：US20070117807A1

  公开（公告）日：2007-05-24

  The present invention is related to a process for preparing anthranilamides of formula I, in which R(1) to R(7) have the meanings indicated herein, a process for their preparation, their use as medicaments, and pharmaceutical preparations containing them. The compounds act on the Kv1.5 potassium channel and inhibit a potassium current which is referred to as the ultra-rapidly activating delayed rectifier in the atrium of the human heart. The compounds are therefore suitable for use as novel antiarrhythmic agents for the treatment and prophylaxis of atrial arrhythmias (e.g., atrial fibrillation (AF) or atrial flutter).

  本发明涉及一种制备式I的蒽酰胺的方法，其中R（1）至R（7）具有本文中所示的含义，其制备方法，作为药物的使用以及含有它们的制药制剂。该化合物对Kv1.5钾通道产生作用，并抑制被称为人类心房中超快速激活延迟整流器的钾电流。因此，该化合物适用于作为新型抗心律失常剂用于治疗和预防心房心律失常（例如心房颤动（AF）或心房扑动）。
• US7235690B2
  申请人：——

  公开号：US7235690B2

  公开（公告）日：2007-06-26
• US7332608B2
  申请人：——

  公开号：US7332608B2

  公开（公告）日：2008-02-19
• [EN] SULFONE-CONTAINING PRODRUGS<br/>[FR] PROMEDICAMENTS CONTENANT DU SULFONE
  申请人：ICAGEN INC

  公开号：WO2005113490A1

  公开（公告）日：2005-12-01

  Compounds, compositions and methods are provided which are useful in the treatment of diseases through the modulation of potassium ion flux through voltage-dependent potassium channels. More particularly, the invention provides sulfone-containing prodrugs, and compositions and methods utilizing sulfone-containing prodrugs that are useful in the treatment of diseases by blocking potassium channels associated with the onset or recurrence of the indicated conditions. Exemplary diseases treatable with the compounds, compositions and methods of the invention include sickle cell disease and glaucoma.